Pasithea Therapeutics Corp. (KTTA) closed at $0.58 on November 6, 2026, up 11.3% from the previous close, on volume of 421,368 shares (30-day average 1,064,498).
Data as of November 6, 2026.
Pasithea Therapeutics Corp (KTTA) Gets a Buy from H.C. Wainwright
TipRanks (Thu, 5-Nov 7:26 AM ET)
Short Interest Alert: Most and least shorted sub-$2B healthcare stock at the end of October
Seeking Alpha News (Tue, 3-Nov 10:15 AM ET)
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Globe Newswire (Wed, 28-Oct 4:05 PM ET)
Globe Newswire (Fri, 23-Oct 9:15 AM ET)
Globe Newswire (Mon, 14-Sep 7:00 AM ET)
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
Market Chameleon (Fri, 28-Nov 4:51 AM ET)
KTTA Gains ALS Association Backing: $1 Million Grant Puts PAS-004 in Spotlight for ALS Therapy
Market Chameleon (Wed, 26-Nov 5:28 AM ET)
Market Chameleon (Mon, 24-Nov 4:53 AM ET)
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Pasithea Therapeutics Corp. trades on the NASDAQ stock market under the symbol KTTA.
As of November 6, 2026, KTTA stock price climbed to $0.58 with 421,368 million shares trading.
KTTA has a beta of 6.06, meaning it tends to be more sensitive to market movements. KTTA has a correlation of 0.13 to the broad based SPY ETF.
KTTA has a market cap of $19.34 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, KTTA traded as high as $17.40 and as low as $.28.
The top ETF exchange traded funds that KTTA belongs to (by Net Assets): VXF.
KTTA has underperformed the market in the last year with a return of -21.2%, while SPY returned +9.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in KTTA shares. However, KTTA has outperformed the market in the last 3 month and 2 week periods, returning +28.6% and +30.0%, while SPY returned -4.2% and -3.8%, respectively. This indicates KTTA has been having a stronger performance recently.
KTTA support price is $.47 and resistance is $.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KTTA shares will trade within this expected range on the day.
